HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270008318670v1 48/7/812    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hu, C. Articles by Zhou, H. Search for Related Content PubMed PubMed Citation Articles by Hu, C. Articles by Zhou, H. Social Bookmarking                         What's this?

An Improved Approach for Confirmatory Phase III Population Pharmacokinetic Analysis

From Pharmacokinetics, Modeling & Simulation, Clinical Pharmacology Sciences, Centocor R&D, Inc, Malvern, Pennsylvania.

In contrast to the traditional extensive exploratory approach, the authors propose a confirmatory approach to phase III population pharmacokinetics for regulatory submissions. In their approach, they recommend a prespecified primary analysis based on phase I/II data and phase III study design. Their approach also incorporates several specific sensitivity analyses to evaluate the robustness of the conclusions. According to statistical rationale, this approach eliminates certain biases that may occur in the estimated covariate effects, thereby precluding potentially unnecessary dosing adjustments and allowing for more accurate assessments of ambiguity in the results. Because exploration is vastly reduced, the analysis time is also substantially shortened. The proposed analyses are relatively easy to implement, although careful and prospective planning is required. Applications of the approach are provided, including 2 phase III analyses for regulatory submissions. Differences between the proposed approach and the commonly used extensive exploratory analyses submitted to regulatory agencies were small and consistent with practical expectations.

Key Words: Nonlinear mixed effect modeling • sparse sampling • drug-drug interaction

Address for reprints: Chuanpu Hu, PhD, Pharmacokinetics, Modeling & Simulation, Clinical Pharmacology Sciences, Centocor R&D, Inc, C-4-5, 200 Great Valley Parkway, Malvern, PA 19355; e-mail: CHu25{at}cntus.jnj.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Zhu, C. Hu, M. Lu, S. Liao, J. C. Marini, J. Yohrling, N. Yeilding, H. M. Davis, and H. Zhou Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis J. Clin. Pharmacol., February 1, 2009; 49(2): 162 - 175. [Abstract] [Full Text] [PDF]